BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Life, 2021 Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen +2 more
doaj +1 more source
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds [PDF]
, 2017 Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit ...
Abhishek Saxena +3 more
core +1 more source
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Frontiers in Immunology, 2023 The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia +24 more
doaj +1 more source
Single-domain antibodies and their formatting to combat viral infections [PDF]
, 2018 Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies +4 more
core +2 more sources
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
Antibodies, 2019 In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang +10 more
doaj +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
How to improve the quality of comparisons using external control cohorts in single-arm clinical trials? [PDF]
arXiv, 2022 PURPOSE Providing rapid answers and early acces to patients to innovative treatments without randomized clinical trial (RCT) is growing, with benefit estimated from single-arm trials. This has become common in oncology, impacting the approval pathway of health technology assessment agencies.
arxiv
Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial [PDF]
, 2011 Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients ...
Grützner, Klaus-Uwe +10 more
core +1 more source
Antibody Watch: Text Mining Antibody Specificity from the Literature [PDF]
PLOS Computational Biology, 2021, 2020 Antibodies are widely used reagents to test for expression of proteins and other antigens. However, they might not always reliably produce results when they do not specifically bind to the target proteins that their providers designed them for, leading to unreliable research results.
arxiv +1 more source
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]
, 2018 Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S +24 more
core +1 more source